Mostrar el registro sencillo del ítem
dc.contributor.author
Rivero, Ezequiel Mariano
dc.contributor.author
Perez, Cecilia
dc.contributor.author
Gargiulo, Lucía
dc.contributor.author
Entschladen, Frank
dc.contributor.author
Zänker, Kurt
dc.contributor.author
Bruzzone, Ariana
dc.contributor.author
Luthy, Isabel Alicia
dc.date.available
2017-09-18T19:54:17Z
dc.date.issued
2017
dc.identifier.citation
Rivero, Ezequiel Mariano; Perez, Cecilia; Gargiulo, Lucía; Entschladen, Frank; Zänker, Kurt; et al.; The β2-adrenergic agonist salbutamol inhibits migration, invasion and metastasis of the human breast cancer MDA-MB-231 cell line; Bentham Science Publishers; Current Cancer Drug Targets; 17; 2017; 1-14
dc.identifier.issn
1568-0096
dc.identifier.uri
http://hdl.handle.net/11336/24518
dc.description.abstract
Background: Breast cancer is the most diagnosed and the major cause of cancer death in women worldwide. Metastasis is the main cause of these deaths. The metastatic cascade involves multiple steps and it has been described that adrenergic receptors can modulate this process at multiple levels. However, β-adrenergic action in breast cancer is controversial. We have previously shown that β-adrenergic agonists inhibit cell proliferation and tumor growth of numerous breast cancer models. Objective: The purpose of the present investigation was to evaluate adrenergic effect in parameters related to tumor progression (migration, invasion and metastases) in two human breast cancer cell lines. Method: Migration was assessed in IBH-6 and MDA-MB-231 cells by time-lapse videomicroscopy and modified Boyden chambers. Invasion was evaluated by Transwells coated with Matrigel and expression of pro-metastatic genes was determined by RT-qPCR. Experimental metastases studies were performed by injection of the cells in the tail vein of NSG immuno-deficient mice. Results: In both cell lines, salbutamol (β2-agonist) and propranolol (β-blocker) significantly diminished cell migration while epinephrine exerted opposite effects. Moreover, salbutamol inhibited invasion of both breast cancer cell lines and enhanced adhesion to extracellular matrix. Salbutamol treatment was also able to decrease the expression of pro-metastatic genes in MDA-MB-231 cells. Finally, this compound decreased the number and size of MDA-MB-231 lung experimental metastases in NSG immuno- deficient mice. No effect on the establishment of IBH-6 metastases was observed. Conclusion: Our results suggest that salbutamol could be an effective adjuvant drug for the treatment of metastatic breast cancer.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Bentham Science Publishers
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Breast Cancer
dc.subject
Metastasis
dc.subject
Adrenoceptors
dc.subject
Salbutamol
dc.subject
Mda-Mb-231
dc.subject
Ibh-6
dc.subject.classification
Bioquímica y Biología Molecular
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.subject.classification
Patología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
The β2-adrenergic agonist salbutamol inhibits migration, invasion and metastasis of the human breast cancer MDA-MB-231 cell line
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2017-09-06T19:37:54Z
dc.identifier.eissn
1873-5576
dc.journal.volume
17
dc.journal.pagination
1-14
dc.journal.pais
Emiratos Árabes Unidos
dc.conicet.avisoEditorial
El manuscrito publicado está disponible en EurekaSelect a través de http://www.eurekaselect.com/openurl/content.php?genre%20=%20article%20&%20doi%20=10.2174/1568009617666170330151415
dc.description.fil
Fil: Rivero, Ezequiel Mariano. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil
Fil: Perez, Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil
Fil: Gargiulo, Lucía. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.description.fil
Fil: Entschladen, Frank. Witten/Herdecke University; Alemania
dc.description.fil
Fil: Zänker, Kurt. Witten/herdecke University; Alemania
dc.description.fil
Fil: Bruzzone, Ariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Investigaciones Bioquímicas de Bahía Blanca. Universidad Nacional del Sur. Instituto de Investigaciones Bioquímicas de Bahía Blanca; Argentina
dc.description.fil
Fil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
dc.journal.title
Current Cancer Drug Targets
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.eurekaselect.com/151233/article
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2174/1568009617666170330151415
Archivos asociados